Antibe Therapeutics Inc (ATBPF PINK) stock market data APIs
$0.2161
0(0%)
as of March 24, 2025
Antibe Therapeutics Inc Financial Data Overview
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada. As of March 17, 2025, Antibe Therapeutics Inc. operates as a subsidiary of Taro Pharmaceuticals Inc.
Prev. Close
0.2161
Open
0.2161
High
0.2161
Low
0.2161
52 wk Range
0.111-0.335
Market Cap
11 450 K
Shares Outstanding
53 009 K
Revenue
9 713 K
EPS
-0.08
Beta
0.345
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Antibe Therapeutics Inc data using free add-ons & libraries
Get Antibe Therapeutics Inc Fundamental Data
Antibe Therapeutics Inc Fundamental data includes:
- Net Revenue: 9 713 K
- EBITDA: -20 447 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-02-14
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Antibe Therapeutics Inc News
New
Antibe Therapeutics Inc.'s (TSE:ATE) Path To Profitability
We feel now is a pretty good time to analyse Antibe Therapeutics Inc.'s (TSE:ATE) business as it appears the company may be on the cusp of a considerable accomplishment. Antibe Therapeutics Inc., a bi...
Antibe Reports 2023 Year-End Results and Business Highlights
- Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway - PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 - Ended year with $3...
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit
TORONTO, April 25, 2023--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapie...
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 18, 2023--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapie...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
